L-R: Nick Shipp (moderator), Kilburn & Strode, and panellists Caleb Bates, Isomorphic Labs; Kiran Patel, Philips; and BC Moore, Illumina

23 October 2025NewsAmericasMarisa Woutersen

The hidden code in life sciences deals

As IP plays a more important role in corporate valuations, acquirers are discovering that the biggest risks in life sciences deals aren’t always in the patents—they’re in the code, the algorithms, and the data. A panel at LSPN North America Fall shared why traditional due diligence is no longer enough.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Less is more: patent lawyers flip the script after Amgen

22 October 2025 The Supreme Court’s 2023 Amgen ruling turned patent strategy upside down. Now lawyers are rethinking everything they thought they knew about protecting inventions. Marisa Woutersen reports from LSPN North America–Fall.

Biotechnology

‘Doing more with less’: In-house counsel on budgets and strategy

22 October 2025 Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.

Americas

Data and delivery: Inside AI's inventorship dilemma

21 October 2025 Isomorphic Labs' head of IP shares why the first wave of AI-driven drug development stumbled, how data became pharma's most valuable currency, and why inventorship questions could make or break billion-dollar deals in machine learning.

More features

Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?

Why AI is changing the patent rules faster than anyone can keep up

LSPN panel unpacks critical IP risks in deal-making

A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order